CN114949034A - Application of perilla frutescens or extract thereof in preparation of medicine for preventing and treating acute pneumonia - Google Patents
Application of perilla frutescens or extract thereof in preparation of medicine for preventing and treating acute pneumonia Download PDFInfo
- Publication number
- CN114949034A CN114949034A CN202210511606.6A CN202210511606A CN114949034A CN 114949034 A CN114949034 A CN 114949034A CN 202210511606 A CN202210511606 A CN 202210511606A CN 114949034 A CN114949034 A CN 114949034A
- Authority
- CN
- China
- Prior art keywords
- extract
- perilla frutescens
- medicine
- lung
- perilla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000124853 Perilla frutescens Species 0.000 title claims abstract description 55
- 235000004348 Perilla frutescens Nutrition 0.000 title claims abstract description 54
- 239000000284 extract Substances 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims description 13
- 210000004072 lung Anatomy 0.000 claims abstract description 50
- 230000004054 inflammatory process Effects 0.000 claims abstract description 32
- 206010061218 Inflammation Diseases 0.000 claims abstract description 31
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 230000008595 infiltration Effects 0.000 claims abstract description 11
- 238000001764 infiltration Methods 0.000 claims abstract description 11
- 230000006378 damage Effects 0.000 claims abstract description 10
- 210000004969 inflammatory cell Anatomy 0.000 claims abstract description 10
- 230000001575 pathological effect Effects 0.000 claims abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 26
- 235000004347 Perilla Nutrition 0.000 claims description 18
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 18
- 241000119909 Elsholtzia bodinieri Species 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 239000003208 petroleum Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- 238000002390 rotary evaporation Methods 0.000 claims description 10
- 238000002137 ultrasound extraction Methods 0.000 claims description 8
- 238000000967 suction filtration Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 abstract description 12
- 229930014626 natural product Natural products 0.000 abstract description 4
- 230000002685 pulmonary effect Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 22
- 210000002381 plasma Anatomy 0.000 description 18
- 102000004889 Interleukin-6 Human genes 0.000 description 16
- 108090001005 Interleukin-6 Proteins 0.000 description 16
- 239000002158 endotoxin Substances 0.000 description 16
- 229920006008 lipopolysaccharide Polymers 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 238000003304 gavage Methods 0.000 description 14
- 239000012530 fluid Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 10
- 102000003896 Myeloperoxidases Human genes 0.000 description 9
- 108090000235 Myeloperoxidases Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 102000003777 Interleukin-1 beta Human genes 0.000 description 8
- 108090000193 Interleukin-1 beta Proteins 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 8
- 239000001993 wax Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000012188 paraffin wax Substances 0.000 description 7
- 239000000401 methanolic extract Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000002020 sage Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000009210 therapy by ultrasound Methods 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000061182 Coleus blumei Species 0.000 description 1
- 235000002659 Coleus scutellarioides Nutrition 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000131458 Elsholtzia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- MGYBYJXAXUBTQF-TWJLCPPASA-N Luteolin rutinoside Chemical compound OC1[C@@H](O)[C@@H](O)C(C)O[C@H]1OCC1[C@@H](O)[C@H](O)C(O)[C@H](OC=2C=C3C(C(C=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 MGYBYJXAXUBTQF-TWJLCPPASA-N 0.000 description 1
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 1
- SHPPXMGVUDNKLV-UHFFFAOYSA-N Veronicastroside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SHPPXMGVUDNKLV-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- BCMSQWPLFBUUKW-IXLPVNPSSA-M cefuzonam sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=CN=NS1 BCMSQWPLFBUUKW-IXLPVNPSSA-M 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- MGYBYJXAXUBTQF-FSFUDZCRSA-N luteolin 7-O-rutinoside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](Oc3cc(O)c4C(=O)C=C(Oc4c3)c5ccc(O)c(O)c5)[C@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@H]1O MGYBYJXAXUBTQF-FSFUDZCRSA-N 0.000 description 1
- 229940043357 mangiferin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- MGYBYJXAXUBTQF-UHFFFAOYSA-N scolymoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 MGYBYJXAXUBTQF-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of perilla frutescens or an extract thereof in preparing a medicine for preventing and treating acute pneumonia, wherein the medicine is a medicine for inhibiting lung tissue bronchoalveolar inflammatory cell infiltration and protein exudation, inhibiting expression of related inflammatory factors in lung parts, inhibiting expression of related inflammatory factors in plasma and improving pathological damage caused by pulmonary inflammatory reaction. The perilla frutescens extract can effectively inhibit lung tissue bronchoalveolar inflammatory cell infiltration and protein exudation of an acute lung injury model mouse under a lower dose, inhibit expression of related inflammatory factors in lung and plasma of an inflammation model mouse, and effectively improve pathological damage caused by inflammatory reaction of the lung of the mouse; the raw materials of the invention are from natural products, and the invention has convenient collection and high safety.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to application of perilla frutescens or an extract thereof in preparing a medicine for preventing and treating acute pneumonia.
Background
An ideal model for researching the inflammatory reaction of the lung is an animal acute lung injury model, and although researchers deeply research the acute lung injury in laboratories and clinics, the lethality rate is still very high. In addition, the current western medicines for treating acute lung injury have large side effects and are easy to generate drug resistance. In order to prevent or treat the acute pneumonia, a safe and effective medicine for preventing or treating the acute pneumonia is urgently sought from natural products.
Eastern perilla (elsholtziabodinieri vaniot) is a perennial herb of the genus elsholtzia of the family labiatae, and is mainly distributed in parts of Yunnan, Guizhou and Gansu. The perilla frutescens is a traditional plant used for both food and medicine, namely camellia sinensis, pine tea and the like in Yunnan, and branches and leaves of the perilla frutescens are soaked in water to serve as herbal tea for drinking in a plurality of minority regions, so that the perilla frutescens has the effects of clearing heat and reducing internal heat, and is a natural health-care beverage. In addition, the perilla frutescens has pungent property and is used as a medicine by whole herbs, which are recorded in national Chinese herbal medicine assembly and Yunnan Chinese herbal medicine, and has the efficacies of relieving fever, easing pain, stopping vomiting, diminishing inflammation, resisting virus and the like. It is reported that the Elsholtzia bodinieri Vahl is rich in triterpenes, aromatic oils, flavonoids, etc., and the extract thereof has antioxidant, antifatigue and antiviral activities, and the Elsholtzia bodinieri Vahl extract is safe without mutagenic effects. However, at present, no patent literature reports about the anti-inflammatory research of the perilla frutescens extract at home and abroad. The research related to the patent is funded by national science fund (approval number: 32160106).
Disclosure of Invention
In order to solve the technical problems, the invention provides a new application of the perilla frutescens or the extract thereof in the aspect of medicine, and the perilla frutescens or the extract thereof is applied to the preparation of a new medicine for preventing and/or treating acute pneumonia.
In order to achieve the purpose, the invention adopts the following technical scheme:
the first purpose of the invention is to provide an application of the perilla frutescens or the extract thereof in preparing a medicine for preventing and treating acute pneumonia, wherein the medicine is used for inhibiting infiltration and protein exudation of bronchoalveolar inflammatory cells of lung tissues, inhibiting expression of related inflammatory factors in lung parts, inhibiting expression of related inflammatory factors in plasma and improving pathological damage caused by pulmonary inflammatory reaction.
Further, the perilla frutescens extract is prepared by the following method:
(1) pulverizing Elsholtzia bodinieri Van to powder, and decolorizing Elsholtzia bodinieri Van powder: adding petroleum ether, performing suction filtration after ultrasonic treatment, and performing rotary evaporation to recover the petroleum ether to obtain the perilla frutescens residue;
(2) airing the residues of the east perilla in the step (1), adding 80% methanol solution, carrying out ultrasonic extraction, and carrying out suction filtration to obtain east perilla filter residues;
(3) adding 80% methanol solution into the east perilla filter residue in the step (2) to perform ultrasonic extraction for 2-3 times, and combining the extracting solutions; rotary distilling the extract to recover methanol until a water phase is obtained; and continuously performing rotary evaporation and concentration on the water phase to obtain a concentrated solution, pre-freezing the concentrated solution in a refrigerator at the temperature of-20 ℃, and freeze-drying by using a freeze dryer to obtain the perilla frutescens 80% methanol solution extract (freeze-dried powder).
Further, in the step (1), the mass-to-volume ratio of the perilla frutescens powder to the petroleum ether is 1g:10 mL.
Further, the ultrasound in the step (1) is ultrasound for 30-35 min under the power of 60-70 w; the rotary evaporation for recovering petroleum ether is carried out for 3 times.
Further, in the step (2) and the step (3), the mass-to-volume ratio of the east perilla residue to the methanol solution and the mass-to-volume ratio of the east perilla residue to the methanol solution are both 1g:10 mL.
Further, the ultrasonic extraction in the step (2) and the step (3) is performed for 30-35 min under the power of 300-320 w.
In the invention, the concentration of the perilla frutescens extract in the medicine for preventing and treating acute pneumonia is preferably 200 mg/kg-600 mg/kg. The invention has no special requirements on the dosage form of the medicine, the auxiliary materials of the medicine and the preparation method of the medicine, and the invention can adopt the methods well known by the technical personnel in the field. The new medicine for preventing and/or treating acute pneumonia is prepared by using the extract of the east perilla as an active ingredient, is used for preparing the medicine for preventing and treating acute pneumonia, and can be added with one or more auxiliary materials acceptable in pharmaceutical preparations or compounded with other active ingredients to play a role in synergistically resisting acute pneumonia.
The invention carries out series research on the perilla frutescens or the extractive thereof for preventing and treating acute pneumonia. The perilla frutescens extract is proved to be capable of remarkably inhibiting infiltration of lung tissue bronchoalveolar inflammatory cells and protein exudation; can obviously inhibit the expression of relevant inflammatory factors in the lung and plasma of an inflammation model mouse; can effectively improve pathological damage caused by inflammatory reaction of the lung of the mouse; the lung inflammation of lipopolysaccharide-induced acute lung injury model mice is effectively improved and the lung function of the lipopolysaccharide-induced acute lung injury model mice is improved, and the effect on preventing or treating acute pneumonia is almost equivalent to that of a blank control group. The perilla frutescens or the extract thereof provided by the invention has a remarkable effect on preventing and treating acute pneumonia, and the perilla frutescens plant is wide in distribution, high in safety, low in price and easy to obtain raw materials; the perilla frutescens or the extract thereof has good development and application prospects in preparation of the medicine for preventing and treating acute pneumonia.
In summary, compared with the prior art, the invention has the advantages that:
1. the invention explores a new medical application of the perilla frutescens extract.
2. Experiments show that the perilla frutescens extract can effectively inhibit lung tissue bronchoalveolar inflammatory cell infiltration and protein exudation of an acute lung injury model mouse under a lower dose, inhibit expression of related inflammatory factors in lungs and plasma of an inflammation model mouse, and effectively improve pathological damage caused by lung inflammatory reaction of the mouse; the raw materials of the invention are from natural products, and the invention has convenient collection and high safety.
3. The perilla frutescens extract has simple extraction process and low cost, and is suitable for industrial production and market popularization and application.
Drawings
FIG. 1 is a diagram showing the results of liquid phase detection of Elsholtzia bodinieri prepared in example 1 of the present invention;
FIG. 2 is a bar graph of the effect of Elsholtzia bodinieri extract on mouse bronchoalveolar lavage fluid cells and proteins, wherein panel A shows the number of bronchoalveolar lavage fluid cells; panel B shows bronchoalveolar lavage fluid protein levels; c is blank control group; model is LPS induction Model group; EBEL is low dose gavage group (200 mg/kg); EBEH was high dose gavage group (600 mg/kg); DXM as positive group (dexamethasone);
FIG. 3 is a graph showing the expression level of the lung inflammatory factor in mice of the present invention, in which FIG. A shows the expression level of IL-6 in lung tissue of mice; FIG. B shows the expression level of IL-1. beta. in lung tissue; FIG. C shows the expression level of MPO in lung tissue; c is blank control group; model is LPS induction Model group; EBEL is low dose gavage group (200 mg/kg); EBEH was high dose gavage group (600 mg/kg); DXM as positive group (dexamethasone);
FIG. 4 is a graph showing the expression level of inflammatory factors in the plasma of mice in accordance with the present invention, wherein FIG. A shows the expression level of IL-6 in the plasma of mice; FIG. B shows the expression level of IL-1. beta. in mouse plasma; FIG. C shows the expression level of NO in mouse plasma; c is blank control group; model is LPS induction Model group; EBEL is low dose gavage group (200 mg/kg); EBEH was high dose gavage group (600 mg/kg); DXM as positive group (dexamethasone);
FIG. 5 is a graph of HE staining of a lung tissue section of a mouse of the present invention, wherein Control is a blank Control group; model is LPS induction Model group; EBEL is low dose gavage group (200 mg/kg); EBEH was high dose gavage group (600 mg/kg); DXM was positive group (dexamethasone).
Detailed Description
The following description of at least one exemplary embodiment is merely illustrative in nature and is in no way intended to limit the invention, its application, or uses. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without any inventive step, are within the scope of the present invention. Techniques, methods, and apparatus known to one of ordinary skill in the relevant art may not be discussed in detail but are intended to be part of the specification where appropriate. In addition, the technical features involved in the different embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
Example 1
Preparation of the perilla frutescens extract of this example:
the Elsholtzia bodinieri Hayata is collected from Yunnan Wenshan, and is naturally dried and pulverized to obtain the Elsholtzia bodinieri Hayata dry powder. Weighing 50g of dry powder of the whole herb of the east perilla, adding petroleum ether, performing ultrasonic treatment for 30min under the power of 60w, wherein the mass-volume ratio of the dry powder of the east perilla to the petroleum ether is 1g:10mL, performing suction filtration, performing rotary evaporation and recovery on part of the petroleum ether, repeating the process for 3 times, and keeping the residue of the east perilla. Air drying the decolorized residues of the east perilla, adding 80% methanol, performing ultrasonic treatment at 300w power for 30min, wherein the mass volume ratio of the east perilla to the methanol is 1g:10mL, performing suction filtration, adding 80% methanol into the obtained residues of the east perilla, performing ultrasonic treatment at 300w power for 30min, and repeating the steps for 3 times; then extracting by rotary evaporation to obtain only water phase in a rotary evaporation bottle, recovering methanol, continuously carrying out rotary evaporation and concentration on the water phase, then prefreezing in a refrigerator at-20 ℃, and finally freeze-drying by a freeze dryer to obtain the perilla frutescens 80% methanol extract (freeze-dried powder).
The main chemical components of the Elsholtzia bodinieri Van 80% methanol extract were qualitatively analyzed by UPLC-MS/MS technique, and the analysis results are shown in FIG. 1.
As can be seen from fig. 1: the 9 main chemical components of the eastern perilla 80% methanol extract are quinic acid (1), chlorogenic acid (2), apigenin (3), Luteolin-7-O-rutinoside (4), mangiferin (5), Luteolin (6), cosmosin (7), rosmarinic acid (8), and eridol 7-O- (6' -3, 4-dihydroxycinnamyl) -beta-D-glucopyranoside (9).
The invention provides application of the perilla frutescens extract obtained by the preparation method in preparation of a medicine for treating acute pneumonia.
The invention also provides application of the perilla frutescens extract in preparing a medicine for preventing and treating acute pneumonia by inhibiting lung tissue bronchoalveolar inflammatory cell infiltration and protein exudation.
The invention also provides application of the perilla frutescens extract in preparing a medicine for preventing and treating acute pneumonia by inhibiting expression of related inflammatory factors in lung.
The invention also provides application of the perilla frutescens extract in preparing a medicine for preventing and treating acute pneumonia by inhibiting expression of relevant inflammatory factors in blood plasma.
The invention also provides application of the perilla frutescens extract in preparing a medicine for preventing and treating acute pneumonia by improving pathological injury caused by pulmonary inflammatory reaction.
Example 2
This example is the evaluation of the activity of the extract of perilla frutescens for preventing and treating acute pneumonia:
2.1 establishment and Experimental Process of acute Lung inflammation mouse model
C57BL/6J male mice (8 weeks old, weighing about 20 g) were used as subjects, and 15 mice were administered to each group. Acute lung inflammatory reaction is induced by nasal LPS (0.5mg/kg), a mouse acute lung injury model is constructed, and modeling is carried out for 12 hours. The prevention and treatment effect of the sage on LPS-induced acute lung injury mice is evaluated by the sage eastern 80% methanol extract obtained in the gastric lavage example 1; mice were acclimated for 7 days in standard environment after purchase and mice were fed standard chow. The specific experimental procedures and groups are as follows:
blank control group: administering purified water with the same volume as the stomach;
model group: injecting LPS (0.5mg/kg) into a pipette nose according to the weight, and molding for 12 hours;
low dose group of sage dong: continuously administering 200mg/kg of Elsholtzia bodinieri (Vat.) Kuntze 80% methanol extract for 7 days, and molding with LPS for 24 hr before dissection;
the high dose group of sage dong: continuously administering 600mg/kg of 80% methanol extract of Elsholtzia bodinieri (L.) Druce after 7 days of gastric lavage, and molding with LPS for 24h before dissection;
positive control group: performing intragastric administration for 1h before molding, administering 10mg/kg dexamethasone, and then performing nasal infusion of LPS (LPS) (0.5mg/kg) by a pipette according to body weight for 24h after molding;
2.2 testing the effect of active ingredients on the number of bronchoalveolar lavage fluid cells and protein content of model mice:
2.2.1 taking each group of mice, performing tracheal intubation, irrigating bronchoalveolar with precooled PBS, taking lavage fluid, centrifuging for 5 minutes at 4 ℃ at 1500 revolutions, collecting supernatant, and detecting the content of total protein by using a BCA kit; the remaining cells were resuspended in pre-cooled PBS, stained with a complex Richmson stain (Wright-Giemsa) for 4 minutes, washed by centrifugation to remove the stain, and immediately the macrophages and neutrophils were counted separately under the microscope using a hemocytometer.
2.2.2 results of the experiment:
effect of eastern perilla extract on bronchoalveolar lavage fluid cell number and total protein content of model mice:
the alveolar lavage fluid test can be used to evaluate the inflammatory response stage of interstitial lung disease and diagnose lung disease. By analyzing the cell number and the total protein content of the bronchoalveolar lavage fluid, the method can be used for analyzing and detecting the disease condition of certain respiratory diseases, and particularly plays a very important role in researching pathogenesis. When lung infection and inflammation occur, alveolar inflammatory cell infiltration occurs, the number of alveolar lavage fluid cells is obviously increased, bronchoalveolar cell proteins of lung tissues are exuded, and the total protein content of alveolar lavage fluid is also increased.
The invention evaluates the action condition of the perilla frutescens extract on acute lung injury model mice by the number of bronchoalveolar lavage fluid cells and the total protein content of each treated mouse, and the result is shown in figure 2, wherein a graph A shows the number of bronchoalveolar lavage fluid cells, and a graph B shows the amount of bronchoalveolar lavage fluid protein. C is blank control group; model is LPS induction Model group; EBEL is low dose gavage group (200 mg/kg); EBEH was high dose gavage group (600 mg/kg); DXM as positive group (dexamethasone); denotes p < 0.05; denotes p < 0.01.
2.3 detecting the influence of the active ingredients on the expression of the lung tissue inflammatory factor and related proteins of the model mouse:
2.3.1 taking each group of mice, taking lung tissues by aseptic technique, washing with aseptic precooled PBS, taking 100mg of lung tissues, adding 900 mu l of aseptic precooled PBS, homogenizing at 4 ℃, centrifuging, taking supernate, and detecting the expression conditions of IL-6, IL-1 beta and MPO in the lung tissues of each group of mice by using a corresponding kit.
2.3.2 results of the experiment
The inflammatory factors refer to various cytokines involved in inflammatory reaction, and when the lung is stimulated by the outside, the lung cells can generate immune response, secrete a large amount of inflammatory factors and even initiate stronger inflammatory reaction. Typical inflammatory factors include interleukin 6(IL-6), interleukin 1 beta (IL-1 beta), Myeloperoxidase (MPO), and the like. IL-6 is a multi-potent cytokine for proinflammatory and immune regulation, has an inflammation amplification effect, and is involved in the occurrence and development of diseases and the inflammatory response and immune response of organisms. The damage of IL-6 to lung is mainly caused by inflammation caused by lung infection and oxidative stress stimulating local macrophages of lung tissue to activate and promote IL-6 secretion, while IL-6 can activate the aggregation of neutrophils at the inflammation part, thereby releasing a large amount of enzyme and oxygen free radicals, and causing the increase of lung capillary permeability and the degeneration and necrosis of lung epithelial cells. IL-1. beta. is a signal to initiate inflammation. MPO is a heme protein, abundant in neutrophils, synthesized in the bone marrow before entry into the circulation by granulocytes and stored in azure granules. MPO can kill microorganisms in phagocytes by catalyzing and oxidizing chloride ions to generate hypochlorous acid, destroy various target substances, and play a role in various aspects such as organism generation, inflammatory reaction regulation and the like.
According to the invention, the influence of the Elsholtzia bodinieri extract on the acute lung injury mice is examined by detecting the expression conditions of IL-6, IL-1 beta and MPO in the lung tissues of each group of mice by using a corresponding kit, and the effect is shown in figure 3. Wherein Panel A shows the expression level of IL-6 in lung tissue; FIG. B shows the expression level of IL-1. beta. in lung tissue; FIG. C shows the expression level of MPO in lung tissue. C is blank control group; model is LPS induction Model group; EBEL is low dose gavage group (200 mg/kg); EBEH was high dose gavage group (600 mg/kg); DXM as positive group (dexamethasone); denotes p < 0.05.
The results in fig. 3 show that the perilla frutescens extract can significantly reduce the expression of IL-6 (p <0.05), the expression of IL-1 β (p <0.05) and the expression of MPO (p <0.05) in lung tissues of mice as a model of inflammation. Therefore, the perilla frutescens extract can obviously inhibit the expression of the relevant inflammatory factors of the lung of the mouse model with inflammation.
2.4 testing the effect of the active principle on the inflammatory factors in the plasma of model mice:
2.4.1 taking each group of mice, collecting blood by anticoagulation tube eyeballs, centrifuging for 5 minutes at 2500 rpm, taking supernatant plasma, and detecting the expression conditions of IL-6, IL-1 beta and NO in the plasma of each group of mice by using a corresponding kit.
2.4.2 results of the experiment
NO has proinflammatory effect, and at an inflammation part, NO acts on vascular smooth muscle cells to increase cGMP level of the vascular smooth muscle cells, so that blood vessels are dilated, permeability is increased, inflammatory mediators and pain substances can reach the action part, and infiltration of monocytes to the inflammation part is increased in inflammatory reaction. In the course of the pathogenesis of immune inflammation, elevated levels of NO in vivo can affect the pathological process from multiple pathways.
The invention inspects the influence of the perilla alcohol extract on the mice with acute lung injury by detecting the expression conditions of IL-6, IL-1 beta and NO in the blood plasma of each group of mice by using a corresponding kit, and the effect is shown in figure 4. Wherein Panel A shows the expression level of IL-6 in plasma; panel B shows the amount of IL-1. beta. expression in plasma; panel C shows the amount of NO expressed in plasma. C is blank control group; model is LPS induction Model group; EBEL is low dose gavage group (200 mg/kg); EBEH was high dose gavage group (600 mg/kg); DXM as positive group (dexamethasone); denotes p <0.05, denotes p < 0.01.
The results in fig. 4 show that the extract of perilla frutescens can significantly reduce the expression of IL-6 (, p <0.01), the expression of IL-1 β (, p <0.05) and the expression of NO (, p <0.01) in the plasma of mice model for inflammation. Therefore, the perilla frutescens extract can obviously inhibit the expression of related inflammatory factors in the plasma of an inflammation model mouse.
2.5 testing the effect of active ingredients on the lung tissue structure of model mice:
2.5.1 taking each group of mice, taking lung tissues by aseptic technique, washing with sterile precooled PBS, fixing to prepare paraffin sections, and observing the change condition of the tissue structure under a microscope after HE staining.
The preparation method of the paraffin section comprises the following steps:
(1) material taking: fresh lung tissue was fixed with 10% formalin for over 24 h. Taking out the lung tissue from the stationary liquid, flattening the tissue of a target part in a fume hood by using a scalpel, and placing the trimmed tissue and a corresponding label in a dehydration box;
(2) dehydrating and wax dipping: and (5) putting the dehydration box into a dehydration machine for dehydration by gradient alcohol in sequence. The method comprises the following steps of 1, dissolving paraffin I at 65 ℃ for 1h, dissolving paraffin II at 65 ℃ for 1h, dissolving paraffin III at 85% for 2h, dissolving 90% alcohol for 2h, dissolving 95% alcohol for 1h, dissolving absolute ethanol I for 30min, dissolving absolute ethanol II for 30min, dissolving alkylbenzene for 5-10min, xylene I for 5-10min, xylene II for 5-10 min;
(3) embedding: embedding the wax-soaked tissue in an embedding machine. Firstly, molten wax is put into an embedding frame, tissues are taken out from a dehydration box and put into the embedding frame according to the requirements of an embedding surface before the wax is solidified, and corresponding labels are attached. Freezing at-20 deg.C, cooling, solidifying wax, taking out the wax block from the embedding frame, and trimming the wax block;
(4) slicing: placing the trimmed wax block in a paraffin slicer for slicing, wherein the thickness of the wax block is 4 mu m; the slices float on a spreading machine at 40 ℃ warm water to flatten the tissues, the glass slides pick up the tissues, the slices are baked in a 60 ℃ oven, and the slices are taken out and stored at normal temperature for later use after being baked by water, dried and waxed.
HE staining method was as follows:
(1) paraffin section dewaxing to water: sequentially placing the slices into xylene I20 min-xylene II 20 min-absolute ethyl alcohol I5 min-absolute ethyl alcohol II 5 min-75% alcohol 5min, and washing with tap water;
(2) hematoxylin staining: staining the slices in hematoxylin staining solution for 3-5min, washing with tap water, differentiating the differentiation solution, washing with tap water, returning blue to the blue solution, and washing with running water;
(3) eosin staining: the slices are dehydrated for 5min respectively by 85 percent and 95 percent gradient alcohol, and are dyed for 5min in eosin dye solution.
(4) Dewatering and sealing: placing the slices in anhydrous ethanol I5 min-anhydrous ethanol II 5 min-anhydrous ethanol III 5 min-xylene I5 min-xylene II 5min for transparency, and sealing with neutral gum;
(5) microscopic examination and image acquisition and analysis.
2.5.2 results of the experiment
The HE staining was used in this experiment to observe the lung tissue structure of mice, and the results are shown in FIG. 5.
As can be seen from the results in fig. 5, the perilla frutescens extract can significantly reduce inflammatory exudates between bronchoalveolar cells, significantly reduce infiltration of tissue inflammatory cells, and maintain integrity of bronchoalveolar epithelial cells. The results show that the perilla frutescens extract can obviously improve pathological injury caused by lung inflammatory reaction of mice.
The preparation method of the perilla frutescens extract comprises the following steps: adding petroleum ether under 70w power for 35min, or adding petroleum ether under 65w power for 33min, and ultrasonic extracting with 80% methanol under 320w power for 35min or 32min, and mixing the rest with the above extract to obtain Coleus blumei extract for preventing and treating acute pneumonia.
In conclusion, the perilla frutescens extract can obviously inhibit the infiltration of lung tissue bronchoalveolar inflammatory cells and protein exudation; can obviously inhibit the expression of relevant inflammatory factors in the lung and plasma of an inflammation model mouse; can effectively improve pathological injury caused by inflammatory reaction of the lung of the mouse. The perilla frutescens extract provided by the invention has a remarkable effect on preventing and treating acute pneumonia, is prepared from natural products, has high safety and low cost, and is suitable for industrial production and market popularization and application.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
Although embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are exemplary and not to be construed as limiting the present invention, and that those skilled in the art may make variations, modifications, substitutions and alterations within the scope of the present invention without departing from the spirit and scope of the present invention.
Claims (6)
1. The application of the perilla frutescens or the extract thereof in preparing the medicine for preventing and treating acute pneumonia is characterized in that the medicine is a medicine for inhibiting infiltration and protein exudation of lung tissue bronchoalveolar inflammatory cells, inhibiting expression of related inflammatory factors in lung, inhibiting expression of related inflammatory factors in plasma and improving pathological damage caused by lung inflammatory reaction.
2. The use of the perilla frutescens or the extract thereof in the preparation of a medicament for preventing and treating acute pneumonia according to claim 1, wherein the perilla frutescens extract is prepared by the following method:
(1) pulverizing Elsholtzia bodinieri Van to powder, decolorizing the Elsholtzia bodinieri Van powder, adding petroleum ether, performing ultrasonic filtration, and performing rotary evaporation to recover the petroleum ether to obtain Elsholtzia bodinieri Van residue;
(2) airing the residues of the east perilla in the step (1), adding 80% methanol solution, carrying out ultrasonic extraction, and carrying out suction filtration to obtain east perilla filter residues;
(3) adding 80% methanol solution into the east perilla filter residue in the step (2), performing ultrasonic extraction for 2-3 times, and combining the extracting solutions; rotary distilling the extract to recover methanol until a water phase is obtained; and continuously performing rotary evaporation and concentration on the water phase to obtain a concentrated solution, pre-freezing the concentrated solution in a refrigerator at the temperature of-20 ℃, and performing freeze-drying by using a freeze dryer to obtain the perilla frutescens 80% methanol solution extract.
3. The application of the perilla frutescens or the extract thereof in preparing the medicine for preventing and treating acute pneumonia in claim 2 is characterized in that in the step (1), the mass-to-volume ratio of the perilla frutescens powder to the petroleum ether is 1g:10 mL.
4. The use of the perilla frutescens or the extract thereof in the preparation of the medicine for preventing and treating acute pneumonia according to claim 2, wherein the ultrasound in the step (1) is performed for 30-35 min at a power of 60-70 w; the rotary evaporation for recovering petroleum ether is carried out for 3 times.
5. The application of the perilla frutescens or the extract thereof in preparing the medicine for preventing and treating acute pneumonia in claim 2 is characterized in that in the step (2) and the step (3), the mass-to-volume ratio of the perilla frutescens residue to the methanol solution and the mass-to-volume ratio of the perilla frutescens residue to the methanol solution are both 1 g/10 mL.
6. The use of the perilla frutescens or the extract thereof in the preparation of the drug for preventing and treating acute pneumonia according to claim 2, wherein the ultrasonic extraction in the step (2) and the ultrasonic extraction in the step (3) are both ultrasonic extraction at power of 300-320w for 30-35 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210511606.6A CN114949034B (en) | 2022-05-12 | 2022-05-12 | Application of perilla extract in preparing medicine for preventing and treating acute pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210511606.6A CN114949034B (en) | 2022-05-12 | 2022-05-12 | Application of perilla extract in preparing medicine for preventing and treating acute pneumonia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114949034A true CN114949034A (en) | 2022-08-30 |
| CN114949034B CN114949034B (en) | 2023-11-07 |
Family
ID=82981289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210511606.6A Active CN114949034B (en) | 2022-05-12 | 2022-05-12 | Application of perilla extract in preparing medicine for preventing and treating acute pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114949034B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116392518A (en) * | 2023-04-19 | 2023-07-07 | 昆明理工大学 | Application of perilla and extract thereof in preparing medicine for treating chronic pressure brain lesions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156889A (en) * | 2004-04-10 | 2008-04-09 | 云南省药物研究所 | Application of east purple common perilla extractive |
| CN113398222A (en) * | 2020-03-17 | 2021-09-17 | 云南中医药大学 | National medicine composition for exorcising evil spirits and preventing epidemic |
-
2022
- 2022-05-12 CN CN202210511606.6A patent/CN114949034B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156889A (en) * | 2004-04-10 | 2008-04-09 | 云南省药物研究所 | Application of east purple common perilla extractive |
| CN113398222A (en) * | 2020-03-17 | 2021-09-17 | 云南中医药大学 | National medicine composition for exorcising evil spirits and preventing epidemic |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116392518A (en) * | 2023-04-19 | 2023-07-07 | 昆明理工大学 | Application of perilla and extract thereof in preparing medicine for treating chronic pressure brain lesions |
| CN116392518B (en) * | 2023-04-19 | 2024-03-15 | 昆明理工大学 | Application of perilla and extract thereof in preparing medicine for treating chronic pressure brain lesions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114949034B (en) | 2023-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104844723A (en) | Preparation method and application of dendrobium officinale extract | |
| CN115531473B (en) | Compound essential oil for treating skin diseases and pharmaceutical composition containing same | |
| CN111870568B (en) | Anti-allergy itching-relieving plant composition and preparation method and application thereof | |
| CN114949034B (en) | Application of perilla extract in preparing medicine for preventing and treating acute pneumonia | |
| CN105617316A (en) | Antibacterial disinfectant for clinical laboratory and preparation method | |
| CN104208294B (en) | It is a kind of to be used to treat Chinese medicine composition of piglet yellow-white dysentery and preparation method thereof | |
| KR20130121324A (en) | Composition for preventing and treating hangover comprising extracts of leaves of perilla frutescens britton var | |
| CN108619165A (en) | Application of the Polysaccharide from Scutellaria Baicalensis in preparing veterinary drug | |
| CN108542926A (en) | The preparation method and pharmaceutical composition of a kind of purslane extract and its application | |
| CN110882332B (en) | Antibacterial, anti-inflammatory and antiallergic nasal traditional Chinese medicine composition and preparation method and application thereof | |
| CN108969580B (en) | Preparation method and application of blue cloth total tannin | |
| CN112920927A (en) | Traditional Chinese medicine compound vinegar composition and preparation method thereof | |
| Andilala | Safraian (2023). The Effectiveness of Kersen Leaf Extracts (Muntingia calabura L.) on Cutting Wounds Infected with Sthapylococcus Aureus Bacteria | |
| KR20200040427A (en) | Method for producing medicine of skin diseases | |
| KR102223717B1 (en) | The crude drugs composition of decreation or treating chronic obstructive pulmonary disease, phamacopuncture injection of oriental medicinie containing the same and Injection containing the same | |
| CN113069466B (en) | Application of purslane polysaccharide in preparation of acute lung injury resistant medicine | |
| CN116492369B (en) | Traditional Chinese medicine polysaccharide composition with anti-inflammatory and hemostatic effects and application thereof | |
| CN115844933B (en) | Application of clindamycin total flavone in preparing heart failure resisting medicine | |
| CN103083376B (en) | Can be used for the Rhizoma Ligustici extract for the treatment of rhinitis | |
| KR20120060053A (en) | Composition for the anti-inflammatory and analgesia comprising extract of propolis and Sophora japonica complex containing flavonoid | |
| CN106387581A (en) | Preparation technology of chicoric acid enriched fresh echinacea purpurea squeezed juice | |
| CN117100819A (en) | Application of red rice seed coat active extract in preparation of medicine for preventing and treating acute alcoholic liver disease | |
| CN1961911A (en) | Lyophilized powder injection containing red sage root and dalbergia wood volatile oil and preparation method thereof | |
| CN118045115A (en) | Application of QIAGUOTA extract in preparing medicine for preventing and treating Alzheimer disease | |
| CN104523740A (en) | Method for preparing selaginella doederleinii hieron polysaccharide extract product and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |